The American Cancer Society estimates that about 67,440 Americans (34,950 men and 32,490 women) will be diagnosed with ...

引言在与癌症的博弈中，胰腺导管腺癌（PDAC）始终是难以攻克的堡垒，其五年生存率不足10%，素有“癌王”之称。传统研究聚焦于基因突变与免疫逃逸，却忽视了肿瘤微环境中一个隐秘的“共谋者”——周围神经系统。2月17日《Nature》杂志发布的一项突破性研 ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

点击蓝字关注我们【导读】癌症疫苗面临的一个基本挑战，是如何产生对肿瘤抗原具有特异性的长效功能性T细胞。在这项研究中，团队发现针对体细胞突变衍生的新抗原的mRNA脂质体疫苗，可以解决胰腺导管腺癌（PDAC）的这一难题。2025年2月19日，美国纪念斯隆 ...

Pancreatic cancer remains difficult to treat, and is responsible for around 8 percent of all cancer deaths.It also has one of ...

The PAC-MANN test was able to differentiate — 98% of the time — between the blood of someone with pancreatic cancer and the ...

A new blood-based test could diagnose pancreatic cancer much earlier, improving outcomes for people with the disease.

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, ...

Pranathi Perati was running out of time to treat her stage-four pancreatic cancer when she found out she would get another shot: a clinical trial testing a new experimental drug. Perati’s odds ...

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based ...